(b) which antigen is present on a maximum of about 5% non-malignant, human marrow cells and a maximum of about 1% non-malignant, human peripheral blood cells; and

(c) which antigen is not present on non-malignant, mature human myeloid and lymphoid cells].

4. (Twice Amended) The monoclonal antibody of claim 2 that [corresponds to] recognizes a binding site on said antigen which overlaps the binding site on said antigen recognized by the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-8483.

7. (Amended) A hybridoma [The immortal cell line that] which produces a [the] monoclonal antibody of claim 2.

9. (Amended) A hybridoma [The immortal cell line that] which produces a [the] monoclonal antibody of claim 4.

REMARKS

The above amendments are made as a follow-up to a telephone call from the Examiner with respect to claim form.

Claim 2 has been amended to delete redundant matter. The MY10 antigen, recognized by the monoclonal antibody of HB8483, appears on a spectrum of lympho-hematopoietic progenitor cells or colony forming cells, as taught in the specification, page 6, line 11-32. This antigen is found on a maximum of 5% of human bone marrow cells and a maximum of 1% peripheral blood cells (specification, page 5, line 24-27), and it is not found on mature myeloid or lymphoid cells (specification, page 5, line 27-31). These characteristics are inherent to cells carrying the antigen recognized by the antibody of hybridoma HB-8483, so the recitation in the claim is redundant, and the recitation is deleted for that reason.

The specification defines what is meant by "correspondence" between antibodies on page 9, lines 6-8. At the request of the Examiner, this definition has been incorporated into claim 4 in place of the term "corresponds."

Monoclonal antibodies, such as those recited in claims 2 and 4, can be produced in a number of ways (as pointed out in the specification, page 8, first paragraph). However, the most usual way is by means of a hybridoma, as taught in the specification from page 8, second paragraph, through page 9. While the monoclonal antibodies recited in claims 2 and 4 may be produced in any manner which results in a monoclonal antibody within the scope of the claims, claims 7 and 9 have been amended to specifically claim the preferred use of hybridomas as the immortal cell line recited in these claims, in order to advance the prosecution of the subject application.

For the Examiner's convenience and in response to an inquiry from the Examiner, a copy of the restriction requirement from parent application Serial No. 670,740 is enclosed. If a fee is required, please charge our deposit account No. 19-0733.

Respectfully submitted,

By: Dale H. Hoscheit

Dale H. Hoscheit
Registration No. 19,090

by Joseph M. Skerpon
Reg. No 29,864

Banner, Birch, McKie & Beckett
One Thomas Circle, N.W.
Washington, D.C. 20005
(202) 296-5500
DHH/LHP/ceg

Dated: June 26, 1990
Docket No. 1107.021635